MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Eli Lilly and Co.

Atidarymo kaina

SektoriusSveikatos priežiūra

869.01 1.98

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

845.8

Max

871.37

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.8B

8.8B

Pardavimai

2.1B

14B

P/E

Sektoriaus vid.

70.036

57.333

Pelnas, tenkantis vienai akcijai

5.32

Dividendų pajamingumas

0.71

Pelno marža

65.172

Darbuotojai

47,000

EBITDA

1.2B

6.1B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+16.73% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.71%

2.63%

Kitas uždarbis

2025-05-01

Kita Ex Dividend data

2025-05-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-50B

735B

Ankstesnė atidarymo kaina

867.03

Ankstesnė uždarymo kaina

869.01

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Eli Lilly and Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-22 09:26; UTC

Pagrindinės rinkos jėgos

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

2025-04-18 15:57; UTC

Pagrindinės rinkos jėgos

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

2025-04-17 11:52; UTC

Pagrindinės rinkos jėgos

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

2025-04-09 18:18; UTC

Pagrindinės rinkos jėgos

Pharma Shares Reverse Losses After Tariff Pause

2025-04-09 09:39; UTC

Pagrindinės rinkos jėgos

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025-04-04 22:38; UTC

Karštos akcijos

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-04-22 09:31; UTC

Karštos akcijos

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

2025-04-17 18:27; UTC

Svarbiausios naujienos

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

2025-04-17 10:45; UTC

Svarbiausios naujienos

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- WSJ

2025-04-11 16:23; UTC

Įsigijimai, susijungimai, perėmimai

Novo Remade Denmark. Then Came the Stock Selloff. -2-

2025-04-11 16:23; UTC

Įsigijimai, susijungimai, perėmimai

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

2025-04-11 09:30; UTC

Svarbiausios naujienos

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

2025-04-11 05:00; UTC

Svarbiausios naujienos

Wall Street Pulls Back on the Weight-Loss Drug Hype -- Barrons.com

2025-04-10 05:00; UTC

Uždarbis

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

2025-04-08 21:26; UTC

Uždarbis

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2025-04-02 16:53; UTC

Svarbiausios naujienos

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

2025-04-01 22:31; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 21:47; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-03-19 15:54; UTC

Svarbiausios naujienos

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-26 15:14; UTC

Svarbiausios naujienos

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

2025-02-26 14:30; UTC

Svarbiausios naujienos

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

2025-02-10 12:00; UTC

Svarbiausios naujienos

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2025-02-07 10:30; UTC

Svarbiausios naujienos

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

2025-02-06 16:16; UTC

Svarbiausios naujienos
Uždarbis

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

2025-02-06 14:56; UTC

Uždarbis

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

2025-02-06 14:32; UTC

Rinkos pokalbiai
Uždarbis

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

2025-02-06 13:18; UTC

Svarbiausios naujienos
Uždarbis

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Akcijų palyginimas

Kainos pokytis

Eli Lilly and Co. Prognozė

Kainos tikslas

By TipRanks

16.73% į viršų

12 mėnesių prognozė

Vidutinis 1,003.6 USD  16.73%

Aukščiausias 1,124 USD

Žemiausias 888 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Eli Lilly and Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

19

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

732.41 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.